
Money, sex and a Buddhist monk: Head of China's famed Shaolin Temple under investigation
Shi Yongxin, known as 'CEO monk' for his entrepreneurial endeavors that transformed the Buddhist monastery into a commercial empire, is suspected of criminal offenses including embezzlement and misappropriation of project funds and temple assets, the temple's authority said in a statement.
The 59-year-old monk was also accused of seriously violating Buddhist precepts by maintaining 'improper relationships' with multiple women over an extended period and fathering at least one child, according to the statement.
Buddhist monks in China have traditionally been expected to take a vow of celibacy.
'(Shi) is currently under joint investigation by multiple departments. Further information will be released to the public in due course,' the statement added.
CNN has not been able to contact Shi.
Established more than 1,500 years ago in the forested mountains of central China, the Shaolin Temple is both a religious and cultural icon, renowned for its age-old tradition of Zen Buddhism and Shaolin kung fu – a distinct form of Chinese martial arts.
Shi, who became the abbot of the Shaolin Temple in 1999 and was a member of China's rubber-stamp parliament for two decades, has frequently appeared in the media spotlight.
Known as the first Chinese abbot to hold a Master of Business Administration degree, he was often seen globetrotting with an iPhone in hand, meeting world leaders and industry titans – from the late Queen Elizabeth II of Great Britain, late South African president Nelson Mandela, and Henry Kissinger to Apple CEO Tim Cook.
In February, Shi led a delegation of monks from the Shaolin Temple to the Vatican to meet with Pope Francis.
But unflattering headlines have dogged the Buddhist monk for years – including his acceptance of a 1 million yuan ($140,000) car from the local government as a reward for promoting tourism in 2006.
Responding to a public outcry at the time, Shi told state media: 'Monks are also citizens. We have fulfilled our duties and made contributions to society, so it is only right that we receive rewards.'
His focus on promoting the Shaolin brand and turning it to multimillion-dollar business has attracted fierce criticism, especially from some followers who saw excessive commercialization as corrupting the spiritual integrity of the religious institution.
He staged Shaolin kung fu performances around the world, licensed the temple's name out to cartoons, movies and video games, and established a business empire that includes publishing, traditional Chinese medicine, tourist development and real estate.
For his part, Shi has defended his efforts to commercialize the Shaolin brand and promote it globally.
After writing a $3 million check to an Australian town in 2015 to build a Shaolin branch there, Shi Yongxin told state-run Xinhua news agency: 'If China can import Disney resorts, why can't other countries import the Shaolin Monastery?'
'Cultural promotion is a very dignified undertaking,' he said.
Later that year, a self-identified Shaolin insider posted a series of explosive allegations on Chinese social media, depicting Shi as an embezzler and womanizer with illegitimate children.
The accuser included documents dating back to the late 1980s purportedly showing Shi being kicked out of Shaolin following theft and other accusations from his own master. Among the documents posted online was a birth certificate for one of the abbot's supposed illegitimate children, as well as photos of the alleged mother and the child.
The allegations prompted an angry denial from the Shaolin Temple and an investigation from the country's religious affairs authorities. Asked by BBC Chinese at the time about the allegations, Shi said: 'If there were a problem, it would have surfaced long ago.'
The authorities dropped the case in 2017, citing insufficient evidence. Three years later, Shi went on to be re-elected as the deputy head of the Buddhist Association of China – the state supervisory body on the religion – a position he has held since 2002.
Steven Jiang contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Trump's Decision to Fire BLS Chief Echoes Putin's Strategies
U.S. President Donald Trump shake hands with Vladimir Putin in Helsinki, on July 16, 2018. Credit - Brendan Smialowski—Getty Images President Donald Trump's firing of the Commissioner of the Bureau of Labor Statistics (BLS) on Friday afternoon just after she delivered a negative jobs report echoes the impulse of many leaders to shoot the messenger. Trump declared, 'I've had issues with the numbers for a long time. We're doing so well. I believe the numbers were phony like they were before the election and there were other times. So I fired her, and I did the right thing.' While Trump may or may not be friends with Vladimir Putin, he is clearly following the Russian President's HR staffing guidelines to eliminate lieutenants who bring bad news. As we've documented before, the Federal State Statistics Service (Rosstat) has a long history of manipulating official economic statistics to please Putin, 'bending over backward to correct bad numbers and burying unflattering statistics' under the pressure the Kremlin has exerted to corrupt statistical integrity, especially since Putin's invasion of Ukraine in 2022. The reliability of official statistics from China has also been brought into question, leading analysts to rely on a wide range of unofficial or proxy indicators to gauge the true state of the Chinese economy. Even China's former Premier, the late Li Keqiang, reportedly confided that he didn't trust official GDP numbers. Read More: What to Know About the Jobs Report That Led Trump to Fire the Labor Statistics Chief Like other strongmen, Trump has repeatedly shown a pattern of manipulating data to suit his preferred narrative. Trump's surprise firing of BLS Commissioner Erika McEntarfer has quickly caught the attention of technical market analysts and economists on both sides of the political spectrum. One side cheers the push to disrupt a slow, bureaucratic federal agency. The other side shouts in dismay over concerns about yet another example of Trump politicizing an apolitical institution. Both responses are warranted. The accuracy of BLS data has long been questioned as major revisions only come in months later. To their credit, the BLS, in addition to other statistical agencies, has publicly recognized a need to modernize its methodology. Unfortunately, though, the severity of job revisions has worsened since the COVID-19 era, with no successful program to address the issue. The downward revision on Friday of more than 250,000 jobs marked the most significant adjustment since the depths of the pandemic. However, Trump's accusations against the BLS of rigging the job numbers to make him and the Republican base look bad, and his subsequent firing of McEntarfer based on a belief that BLS revisions were politically motivated, are yet another step closer to authoritarianism. Introducing his latest conspiracy theory, the President went even further by suggesting McEntarfer, whose career spans two decades across Republican and Democratic Administrations, rigged the numbers 'around the 2024 presidential election' in then-Vice President Kamala Harris' favor. Trump conveniently fails to mention that his definition of 'around' was back in August 2024. Recall, the 2024 presidential election was a full three months later in November. Revisions are not unusual behavior by the BLS. They are a critical part of the natural process for developing an accurate picture of the largest, most dynamic economy in the world. The average size of job revisions since 2003 is not insignificant at 51,000 jobs. And, despite what Trump may want Americans to believe, his tariff policies have created an unprecedented level of uncertainty in the U.S. economy, comparable only to that of 2020, with many economists expecting a recession to follow as a result. Bloomberg reporting has pointed to a possible connection between the severity of negative job revisions and recessionary economic environments. The BLS has also been subjected to DOGE-led hiring constraints and other resource rescissions. In addition, the Trump Administration's disbanding of the Federal Statistics Advisory Committee in March both eliminated one of the main engines for enhancing agency performance and, perhaps, in what should have been a concerning harbinger, abolished the canary in the data integrity coal mine. Complaints about BLS methods are legitimate, like the reliance on enumerators over scanner data, and deserve attention, but this is not how to fix it. Read More: What Trump's Win Means for the Economy This is far from the first time Trump has subordinated statistical integrity to political theater. From crowd sizes to weather forecasts, vote counts to tariff formulas, Trump has discarded facts for fictions that play to his political favor. Trump doesn't just bend the truth—he twists the numbers until they resemble propaganda and then silences those who disagree. As CBS News titan Edward R. Murrow warned 65 years ago: 'To be persuasive, we must be believable. To be believable, we must be credible. To be credible, we must be truthful.' Contact us at letters@
Yahoo
2 hours ago
- Yahoo
Pharma interest can plug NIH funding gap: Illumina CEO
Genetic sequencing company Illumina (ILMN) has had a rough few years. It has battled activist investors, faced off with the Federal Trade Commission, and, most recently, agreed to a $9.8 million settlement with the Department of Justice over a cybersecurity breach. To add to the pile: sanctions in China and the Trump administration cutting National Institutes of Health (NIH) funding, which the company relies heavily on for clinical research. The numbers don't lie. The stock is down more than 21% in the past year and sank more than 11% in after-hours trading Thursday after the company reported an earnings miss for the second quarter. The company reported $1.06 billion in revenues compared to expected revenues of $1.05 billion. Adjusted earnings per share came in at $1.19 compared to estimates of $1.01. But CEO Jacob Thaysen told Yahoo Finance he remains positive about the company's near-term growth. Why? Because, in part, pharmaceutical companies can provide a new market. "Now, we're shifting from small things to really big programs. Some of the things making up for the reduction from the NIH is kind of indirect, but pharma is getting more interest in these big programs," he said, noting that 15% of the company is exposed to government research funding. "It's not only about sequencing itself, but really using massive amounts of data ... to really identify new drug targets and understand a disease," Thaysen said. The idea to use patient data to help the pharmaceutical world was also identified by 23andMe, which recently came out of bankruptcy through a nonprofit led by founder Anne Wojcicki. Thaysen said that unlike 23andMe, which he has worked with, his company is not going to pursue drug development on its own. "We have a lot of pharma companies that are very excited to work with us," he said. In addition to genetic testing of patient samples, the company is looking at growing in the preventative side of care with cancer screenings. The oncology business, Thaysen said, will have healthy growth over the next 10 or so years. China China banned importations of the San Diego-based company's sequencing machines earlier this year as part of its retaliatory actions to Trump's tariff war. Thaysen said he is working with regulators to try to reverse that, but "in the meantime, that business is declining, and we are expecting it to be flat." In fact, though China has historically been about 10% of the company's business, it contributed to half of the decline in earnings this past week. "China was never a huge part of Illumina's business. When it was the largest, it was just around 10%. We're down to 5% of the business," Thaysen told Yahoo Finance. But because of the tariff war and China's goals to boost its domestic innovation market, Illumina has faced a setback in its market power there from local competition. "As soon as there is a Chinese alternative that is good enough, then you will see that the Chinese government is pushing for the Chinese population, the Chinese companies to use that technology," Thaysen said. He added that even with the increased competition, China is an appealing market to remain in. Analysts are still waiting to see more progress on Illumina's return to growth. Jefferies analyst Tycho Peterson said in a note to clients that the firm will reiterate its Hold rating until things settle: "While the clinical traction is encouraging, we view clarity on near-term headwinds (A&G, China, Roche) and a path to sustainable HSD growth as key to a more constructive view. Reiterate Hold." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Stryker lowers expected tariff impact to $175M
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q2 revenue: $6 billion 11.1% increase year over year Net income: $884 million 7.2% increase year over year Stryker expects a $175 million tariff impact on earnings in 2025, a slight decrease from the $200 million the company forecast in May. Stryker joins several medical device companies that have slashed tariff expectations, with several firms, including Johnson & Johnson and Boston Scientific, cutting the expected tariff hit by as much as half. Stryker CFO Preston Wells said Thursday on an earnings call that the changes were a result of the U.S. and China agreeing to significantly reduce levies. However, Stryker did not cut its forecast by as much as other companies because the recent trade agreement with the European Union, which set a tariff rate of 15%, was more than the 10% Stryker had included in its previous model. CEO Kevin Lobo said Stryker was impacted less than other companies due to its manufacturing footprint in Europe and having less of a presence in China than other medtech companies. Raised earnings forecast Stryker raised its financial forecast for the year, now expecting organic sales growth in a range of 9.5% to 10%, from a previous range of 8.5% to 9.5%. The company also raised its expectations for adjusted earnings per share by about 20 cents. Lobo said the update was driven by continued procedural strength, including implants, and demand for capital equipment. Wells said initiatives Stryker started during the COVID-19 pandemic, such as pricing and manufacturing efficiency, have helped drive margin improvements. Robot update Stryker shared an update on planned launches for the company's robots. In March, the company unveiled its latest orthopedic robot, the Mako 4. The Food and Drug Administration cleared the new system, but Stryker has not yet rolled out the robot globally, Lobo said. The company has new hip revision and spine surgery applications that are only available on Mako 4. Stryker's shoulder surgery application is currently on its Mako 3 robot, and is in the process of migrating to the newer robot, Lobo said. Because of that, the feature is still in a limited launch until next year. Stryker reported a record quarter for Mako installations, although the company did not disclose the number of robots. The company reached a milestone of 2 million robotic procedures performed with Mako during the second quarter. Recommended Reading Stryker expects $200M tariff hit, lowers earnings forecast Sign in to access your portfolio